THERMO FISHER SCIENTIFIC $TMO Q3’26 EARNINGS HIGHLIGHTS
🔹 Revenue: $12.14B (Est. $11.95B) 🟢; +9% YoY
🔹 Adj. EPS: $6.68 (Est. $6.40) 🟢; +15% YoY
🔹 Organic Revenue Growth: +6%
Other Q3 Metrics:
🔹 Adj. Oper Income: $2.97B (Est. $2.87B) 🟢
🔹 Adj. Net Income: $2.48B (Est. $2.38B) 🟢
🔹 Adj. Oper Margin: 24.5%; +120 bps YoY
🔹 GAAP Oper Margin: 18.6%; +120 bps YoY
🔹 Free Cash Flow: $2.12B; vs $1.84B LY
Segment Revenue:
🔹 Life Sciences Solutions: $2.72B; vs $2.59B LY
🔹 Analytical Instruments: $2.00B; vs $1.89B LY
🔹 Specialty Diagnostics: $1.10B; vs $1.17B LY
🔹 Lab Products & Biopharma: $6.86B; vs $5.97B LY
Key Updates:
🔹 GAAP EPS: $4.64; +9% YoY
🔹 Completed our previously announced divestiture of our microbiology business
🔸 Cost of revenues adjustments: $0.02/share
🔸 Selling, general and administrative expenses adjustments: -$0.06/share
🔸 Restructuring and other costs: $0.54/share
🔸 Amortization of acquisition-related intangible assets: $1.40/share
🔸 Other income/expense adjustments: $0.04/share
🔸 Income taxes adjustments: $0.07/share
🔸 Equity in earnings/losses of unconsolidated entities: $0.02/share
Comments:
🔸 “Looking ahead, we’re well positioned to deliver an excellent 2026 as we continue to drive long-term value creation for all of our stakeholders and build an even brighter future for our company.”
显示更多